Genscript Biotech Corporation (1548) Announces Legend Biotech’s Data Presentation at 2025 ASH Meeting

Bulletin Express11-04

Genscript Biotech Corporation (the Company), listed on the Hong Kong Stock Exchange under stock code 1548, issued a voluntary announcement regarding Legend Biotech Corporation (Legend), an associate of the Company listed on the Nasdaq Global Select Market in the United States. According to the announcement, Legend has filed a Form 6-K with the U.S. Securities and Exchange Commission on 3 November 2025 (New York time) to report that new data on CARVYKTI® and other pipeline projects will be presented at the 67th American Society of Hematology Annual Meeting. The meeting is scheduled for 6 December 2025 to 9 December 2025 in Orlando, Florida.

Legend’s announcement references potential benefits of its product candidates and future plans. The forward-looking statements within that announcement are subject to significant risks and uncertainties, including clinical outcomes, regulatory actions, and other factors outlined in the “Risk Factors” section of Legend’s Annual Report on Form 20-F. The Company’s announcement reiterates that actual results may differ materially as a result of these factors. According to the original text, no obligation exists to update any forward-looking statement, whether due to new information or future events.

Shareholders and potential investors are advised in the Company’s announcement to pay attention to investment risks and exercise caution when dealing in the Company’s securities. The announcement also notes that the English version shall prevail in the event of any inconsistency with the accompanying Chinese translation.

As of 4 November 2025, the executive directors of the Company were listed as Mr. Jiange Meng (Mr. Robin Meng), Dr. Fangliang Zhang (Dr. Frank Zhang), Dr. Li Zhu, and Ms. Ye Wang (Ms. Sally Wang). The independent non-executive directors were Dr. Alphonse Galdes, Mr. Yiu Leung Andy Cheung (Mr. Andy Cheung), Mr. Jiuan Pan (Mr. Ethan Pan), Dr. John Quelch, Dr. Ross Grossman, and Dr. Chenyang Shi (Dr. Victor Shi). The announcement was issued on 4 November 2025 in Hong Kong.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment